Notably, cisplatin downregulated the toll-like receptor signalling pathway, TLR 2/4, along with IL-18, which is required for killer T-cell activation, potentially indicating an attempt by cancer cells to avoid immune destruction. The gene discussed is IL18; the disease is cancer.